[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 617
Citations 0
In This Issue of JAMA
August 9, 2016


JAMA. 2016;316(6):563-565. doi:10.1001/jama.2015.14419

Cerebral emboli are a common risk of transcatheter aortic valve implantation (TAVI). In a clinical trial involving 100 patients with severe aortic stenosis who were randomly assigned to undergo TAVI with or without a cerebral embolism protection (filter) device, Haussig and colleagues found that use of the protection device reduced the frequency of ischemic lesions. In an Editorial, Messé and Mack discuss interventions to improve cerebral safety of high-risk cardiovascular procedures.


Author Video Interview

In an analysis of cross-sectional data from 6251 adults with diabetes who participated in the 1988-2014 National Health and Nutrition Examination Surveys, Afkarian and colleagues found that the overall prevalence of diabetic kidney disease did not change significantly, whereas the prevalence of albuminuria declined and the prevalence of reduced estimated reduced glomerular filtration rate increased.

In a systematic review and network meta-analysis of data from 30 randomized trials (5598 infants) of 7 different ventilation strategies for preterm infants, Isayama and colleagues found that less invasive surfactant administration—involving nasal continuous positive airway pressure without intubation and surfactant administration via a thin diameter tube directly into the trachea—was associated with the lowest likelihood of death or bronchopulmonary dysplasia (BPD) at 36 weeks’ postmenstrual age.

Clinical Review & Education

This US Preventive Services Task Force (USPSTF) Recommendation Statement addresses screening for lipid disorders in children and adolescents. Based on results of 2 separate evidence reviews—screening for multifactorial dyslipidemia and screening for heterozygous familial hypercholesterolemia—the USPSTF concluded the current evidence is insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents. An Editorial by Urbina and de Ferranti discusses benefits and potential harms of lipid screening in children and adolescents.

Editorial and Related Articles 1 and 2

Author Audio Interview and CME

Lozano and colleagues summarize findings from the US Preventive Services Task Force evidence review of the benefits and harms of screening children and adolescents for multifactorial dyslipidemia. The evidence was limited. The review found that the diagnostic yield of screening varies by age and body mass index. No direct evidence addressed benefits or harms of childhood screening or treatment on outcomes in adulthood.

Editorial and Related Articles 1 and 2


Lozano and colleagues summarize findings from the US Preventive Services Task Force evidence review of the benefits and harms of screening children and adolescents for heterozygous familial hypercholesterolemia (FH). The authors report screening detects FH in children, and lipid-lowering treatment can reduce lipid concentrations in the short term with little evidence of harm. However, there was no evidence that childhood screening for FH effects lipid concentrations or cardiovascular outcomes in adulthood or evidence of long-term benefits or harms of beginning lipid-lowering treatment in childhood.

Editorial and Related Articles 1 and 2


An article in JAMA Psychiatry reported clinical details from 66 Dutch patients who received euthanasia or assisted suicide for psychiatric conditions. In this From The JAMA Network article, Olié and Courtet discuss treatment to address impaired decision making and psychological pain in patients with psychiatric disorders who request euthanasia or assisted suicide.

This JAMA Clinical Guidelines Synopsis article provides a summary of Guidelines for the Primary Prevention of Stroke developed by the American Heart Association and the American Stroke Association. Major recommendations include assessing stroke risk using a risk assessment tool; encouraging healthful lifestyle habits; applying guideline-appropriate cholesterol-lowering treatment; and prescribing aspirin for cardiovascular disease prophylaxis for patients with a 10-year risk of cardiovascular disease exceeding 10%.